Immune mechanisms regulating allergy
Immune mechanisms regulating allergy
批准号:
10240308
负责人:
Stephanie Caroline Eisenbarth
金额:
$2.6万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-17 至 2021-12-31
关键词:
AffinityAllergensAllergicAllergic ReactionAnaphylaxisAntibodiesAntibody ResponseAsthmaAutomobile DrivingB-Lymphocyte SubsetsB-LymphocytesCell Differentiation processCell physiologyCellsCytokine ReceptorsCytokinesisDevelopmentDiseaseDissociationEnvironmental Risk FactorExperimental ModelsGATA3 geneGeneticGoalsHelper-Inducer T-LymphocyteHumanHypersensitivityIL4 geneIgEIgG1ImmuneImmune responseImmunizationImmunizeImmunoglobulin Class SwitchingImmunoglobulin MImmunologicsInterleukin-13Interleukin-4Interleukin-5Knockout MiceKnowledgeLifeLongevityMediatingModelingMolecularMusPathologicPathway interactionsPhenotypeProductionRoleSTAT3 geneSignal TransductionStimulusSystemT-LymphocyteT-Lymphocyte SubsetsTestingWild Type MouseWorkairborne allergenbasechemokine receptorconditional knockoutcrosslinkcytokineexperimental studyhelminth infectionin vivomanmast cellmouse modelpreventreceptor expressionresponsetooltranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Cross-linking of high affinity IgE on mast cells results in one of the most life-threatening allergic reactions,
anaphylaxis. Yet the cellular mechanisms that induce B cells to produce IgE to allergens remain poorly
understood. T follicular helper (Tfh) cells are the primary T cell subset responsible for directing the affinity,
longevity and isotype of antibody produced by B cells. Subsets of Tfh cells exist in both mouse and man,
defined by their differential cytokine and chemokine receptor expression. Tfh2 cells are primarily identified by
IL-4 expression during a type 2 immune response and can promote IgE. Whether Tfh2 cells are required for
both low and high affinity IgE is not know. By studying a murine model of a rare monogenic form of IgE-
mediated allergy, DOCK8 (dedicator of cytokinesis 8) deficiency, we recently discovered a new subset of Tfh2
cells that promotes high affinity IgE in vivo. We call this new subset “TfhE” cells and identify them by the
expression of a constellation of cytokine and transcription factors not normally produced by Tfh cells. Further,
the same subset is induced in wild type mice, but only during aeroallergen-driven responses when high affinity
IgE is produced. In contrast, TfhE cells are not induced during low affinity IgE responses. We do not know how
the development of TfhE cells is regulated or how they function to induce IgE. Although IL-4 is necessary for
IgE class switching, it is not sufficient in vivo. Further, the dissociation between low and high affinity production
during different type 2 immune responses suggests that direct versus sequential B cell switching to IgE might
be regulated by different Tfh2 subsets. The goal of our proposed experiments is to fill these crucial gaps in
knowledge and thereby illuminate the pathways that drive production of high affinity IgE and the attendant
anaphylactic allergic reactions. The broad impact of these advances could be substantial, enabling definition of
the genetic and environmental factors that dictate high affinity IgE responses in those with asthma and other
allergic conditions. We have developed tools including Tfh-restricted knockout mice to determine 1) whether
DOCK8 regulates Tfh differentiation in a cell-intrinsic manner and functions similarly in human Tfh cells; 2)
whether high and low affinity IgE are driven by different Tfh cell subsets in wild type mice; 3) molecular
mechanisms controlling wild type TfhE development and function, including the identity of factors that, together
with IL4, are produced by TfhE cells to drive IgE class switching and transcription factor(s) that dictate TfhE
differentiation. If successful, these experiments will define how TfhE cells specifically promote high affinity IgE
and will define molecular pathways that regulate TfhE induction. Inhibition of key pathways operational in these
TfhE cells could be used to promote allergen-specific antibody isotypes that potentially block anaphylaxis.
1
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Determinants of oral anaphylaxis to food
-
批准号:10586739
-
项目类别:
-
资助金额:$80.48万
-
财政年份:2023
-
负责人:Stephanie Caroline Eisenbarth
-
依托单位:
The adaptive immune response to food antigens in the gut
-
批准号:10455274
-
项目类别:
-
资助金额:$44.8万
-
财政年份:2021
-
负责人:Stephanie Caroline Eisenbarth
-
依托单位:
Immune mechanisms regulating allergy
-
批准号:10197629
-
项目类别:
-
资助金额:$0.8万
-
财政年份:2018
-
负责人:Stephanie Caroline Eisenbarth
-
依托单位:
Immune mechanisms regulating allergy
-
批准号:10461080
-
项目类别:
-
资助金额:$62.36万
-
财政年份:2018
-
负责人:Stephanie Caroline Eisenbarth
-
依托单位:
Immune mechanisms regulating allergy
-
批准号:9980783
-
项目类别:
-
资助金额:$61.06万
-
财政年份:2018
-
负责人:Stephanie Caroline Eisenbarth
-
依托单位:
Immune mechanisms regulating allergy
-
批准号:10548673
-
项目类别:
-
资助金额:$60.4万
-
财政年份:2018
-
负责人:Stephanie Caroline Eisenbarth
-
依托单位:
Innate Immune Receptors that Promote RBC Alloimmunization
-
批准号:10192794
-
项目类别:
-
资助金额:$43.46万
-
财政年份:2017
-
负责人:Stephanie Caroline Eisenbarth
-
依托单位:
Regulation of adaptive immunity by the NOD-like receptor NLRP10
-
批准号:9188793
-
项目类别:
-
资助金额:$41.63万
-
财政年份:2013
-
负责人:Stephanie Caroline Eisenbarth
-
依托单位:
Regulation of adaptive immunity by the NOD-like receptor NLRP10
-
批准号:8612109
-
项目类别:
-
资助金额:$41.63万
-
财政年份:2013
-
负责人:Stephanie Caroline Eisenbarth
-
依托单位:
Role of the Nlrp3 Inflammasome in Adaptive Immunity
-
批准号:8081119
-
项目类别:
-
资助金额:$13.35万
-
财政年份:2010
-
负责人:Stephanie Caroline Eisenbarth
-
依托单位:
Role of the Nlrp3 Inflammasome in Adaptive Immunity
-
批准号:8272616
-
项目类别:
-
资助金额:$13.35万
-
财政年份:2010
-
负责人:Stephanie Caroline Eisenbarth
-
依托单位:
Role of the Nlrp3 Inflammasome in Adaptive Immunity
-
批准号:8658800
-
项目类别:
-
资助金额:$13.35万
-
财政年份:2010
-
负责人:Stephanie Caroline Eisenbarth
-
依托单位:
Role of the Nlrp3 Inflammasome in Adaptive Immunity
-
批准号:8461811
-
项目类别:
-
资助金额:$13.35万
-
财政年份:2010
-
负责人:Stephanie Caroline Eisenbarth
-
依托单位:
Role of the Nlrp3 Inflammasome in Adaptive Immunity
-
批准号:7989572
-
项目类别:
-
资助金额:$13.35万
-
财政年份:2010
-
负责人:Stephanie Caroline Eisenbarth
-
依托单位:
Innate Immune Receptors that Promote RBC Alloimmunization
-
批准号:10018092
-
项目类别:
-
资助金额:$43.44万
-
财政年份:--
-
负责人:Stephanie Caroline Eisenbarth
-
依托单位:
海外基金